Exploiting Viruses to Treat Diseases
/in International Publications, Newcastle Disease Virus /von 2018-06-26 / N. Engl. J. Med. 2018 07;379(2):194-196Chemotherapy Sensitizes Therapy-Resistant Cells to Mild Hyperthermia by Suppressing Heat Shock Protein 27 Expression in Triple-Negative Breast Cancer
/in Breast Cancer, Hyperthermia, International Publications /von 2018-06-19 / Clin. Cancer Res. 2018 Oct;24(19):4900-4912Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus
/in Checkpoint-Inhibitors, International Publications, Newcastle Disease Virus /von 2018-06-19 / Oncotarget 2018 Jun;9(47):28702-28716Targeting dendritic cells in pancreatic ductal adenocarcinoma
/in Dendritic Cells, Exosome, International Publications, Pancreatic Cancer /von 2018-06-18 / Cancer Cell Int. 2018;18:85Hyperthermia in cervical cancer – current status
/in Cervical Cancer, Hyperthermia, International Publications /von 2018-06-15 / Rep Pract Oncol Radiother 2018 Nov-Dec;23(6):595-603Zwischenergebnisse zur Anwendung von Dendritischen Zellen beim Glioblastom von Dr. Marnix Bosch
/0 Kommentare/in Externe Meldungen /von rootInterim analysis of a prospective, randomized, double blind, placebo controlled, phase IIb trial of the TLPLDC vaccine to prevent recurrence in resected stage III or IV melanoma patients.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-06-04 / J Clin Oncol 36, 2018 (suppl; abstr 9525)New physical approaches to treat cancer stem cells: a review
/in Hyperthermia, International Publications /von 2018-06-04 / Clin Transl Oncol 2018 Dec;20(12):1502-1521Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Interim analysis of a phase 2, open-label, randomized, multicenter trial.
/in Dendritic Cells, International Publications /von 2018-06-03 / J Clin Oncol 36, 2018 (suppl; abstr 5509)
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution